{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:34:35Z","timestamp":1794602075075,"version":"4.9.1"},"reference-count":275,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0534800"],"award-info":[{"award-number":["2024ZD0534800"]}]},{"name":"Capital's Funds for Health Improvement and Research","award":["2026-1Q-1093"],"award-info":[{"award-number":["2026-1Q-1093"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203881"],"award-info":[{"award-number":["82203881"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science Foundation of Peking University Cancer Hospital","award":["BJCH2025GG03"],"award-info":[{"award-number":["BJCH2025GG03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01803-9","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:17:00Z","timestamp":1777007820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies"],"prefix":"10.1186","volume":"19","author":[{"given":"Yi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"1803_CR1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29:2452\u201368. https:\/\/doi.org\/10.3748\/wjg.v29.i16.2452.","journal-title":"World J Gastroenterol"},{"key":"1803_CR2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3760\/cma.j.cn112151-20250408-00245","volume":"54","author":"[Expert consensus on Claudin","year":"2025","unstructured":"[Expert consensus on Claudin. 18.2 expression testing in gastric cancer (2025 version)]. Zhonghua Bing Li Xue Za Zhi. 2025;54:718\u201325. https:\/\/doi.org\/10.3760\/cma.j.cn112151-20250408-00245.","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"1803_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348. https:\/\/doi.org\/10.1016\/s0140-6736(20)31288-5.","journal-title":"Lancet"},{"key":"1803_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, et al. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21:354\u201369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"1803_CR5","doi-asserted-by":"publisher","first-page":"100589","DOI":"10.1016\/j.modpat.2024.100589","volume":"37","author":"M Fassan","year":"2024","unstructured":"Fassan M, Kuwata T, Matkowskyj KA, R\u00f6cken C, R\u00fcschoff J. Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach. Mod Pathol. 2024;37:100589. https:\/\/doi.org\/10.1016\/j.modpat.2024.100589.","journal-title":"Mod Pathol"},{"key":"1803_CR6","doi-asserted-by":"publisher","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13:954992. https:\/\/doi.org\/10.3389\/fimmu.2022.954992.","journal-title":"Front Immunol"},{"key":"1803_CR7","doi-asserted-by":"publisher","unstructured":"Hashimoto Y, et al. Potential for Tight Junction Protein-Directed Drug Development Using Claudin Binders and Angubindin-1. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20164016.","DOI":"10.3390\/ijms20164016"},{"key":"1803_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1083\/jcb.200110122","volume":"156","author":"M Furuse","year":"2002","unstructured":"Furuse M, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol. 2002;156:1099\u2013111. https:\/\/doi.org\/10.1083\/jcb.200110122.","journal-title":"J Cell Biol"},{"key":"1803_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jmb.2014.10.020","volume":"427","author":"H Suzuki","year":"2015","unstructured":"Suzuki H, Tani K, Tamura A, Tsukita S, Fujiyoshi Y. Model for the architecture of claudin-based paracellular ion channels through tight junctions. J Mol Biol. 2015;427:291\u20137. https:\/\/doi.org\/10.1016\/j.jmb.2014.10.020.","journal-title":"J Mol Biol"},{"key":"1803_CR10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1083\/jcb.141.7.1539","volume":"141","author":"M Furuse","year":"1998","unstructured":"Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and \u2013\u20092: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998;141:1539\u201350. https:\/\/doi.org\/10.1083\/jcb.141.7.1539.","journal-title":"J Cell Biol"},{"key":"1803_CR11","doi-asserted-by":"publisher","unstructured":"Bhat AA et al. Tight Junction Proteins and Signaling Pathways in Cancer and Inflammation: A Functional Crosstalk. Front Physiol 9, 1942, https:\/\/doi.org\/10.3389\/fphys.2018.01942 (2018).","DOI":"10.3389\/fphys.2018.01942"},{"key":"1803_CR12","doi-asserted-by":"publisher","first-page":"113370","DOI":"10.1016\/j.ejca.2023.113370","volume":"195","author":"J Taieb","year":"2023","unstructured":"Taieb J, et al. Treatment of gastric adenocarcinoma: A rapidly evolving landscape. Eur J Cancer. 2023;195:113370. https:\/\/doi.org\/10.1016\/j.ejca.2023.113370.","journal-title":"Eur J Cancer"},{"key":"1803_CR13","doi-asserted-by":"publisher","unstructured":"Chong X, et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol. 2024;17. https:\/\/doi.org\/10.1186\/s13045-024-01578-x.","DOI":"10.1186\/s13045-024-01578-x"},{"key":"1803_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.annonc.2021.02.021","volume":"32","author":"A Athauda","year":"2021","unstructured":"Athauda A, Chau I. Claudin 18.2-a FAST-moving target in gastric cancer? Ann Oncol. 2021;32:584\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.021.","journal-title":"Ann Oncol"},{"key":"1803_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000002464","author":"BL Liu","year":"2025","unstructured":"Liu BL, Cleary JM, Shi J, Hornick JL, Zhao L. Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas. Am J Surg Pathol. 2025. https:\/\/doi.org\/10.1097\/pas.0000000000002464.","journal-title":"Am J Surg Pathol"},{"key":"1803_CR16","doi-asserted-by":"publisher","first-page":"100712","DOI":"10.1016\/j.modpat.2025.100712","volume":"38","author":"KE McHugh","year":"2025","unstructured":"McHugh KE, et al. Claudin 18.2 Expression in 1404 Digestive Tract Adenocarcinomas Including 1175 Colorectal Carcinomas: Distinct Colorectal Carcinoma Subtypes Are Claudin 18.2 Positive. Mod Pathol. 2025;38:100712. https:\/\/doi.org\/10.1016\/j.modpat.2025.100712.","journal-title":"Mod Pathol"},{"key":"1803_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00428-024-03756-1","volume":"485","author":"P Wagner","year":"2024","unstructured":"Wagner P, et al. Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypes. Virchows Arch. 2024;485:63\u201374. https:\/\/doi.org\/10.1007\/s00428-024-03756-1.","journal-title":"Virchows Arch"},{"key":"1803_CR18","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/cas.70100","volume":"116","author":"T Hashimoto","year":"2025","unstructured":"Hashimoto T, et al. Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study. Cancer Sci. 2025;116:2218\u201331. https:\/\/doi.org\/10.1111\/cas.70100.","journal-title":"Cancer Sci"},{"key":"1803_CR19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s10120-024-01505-6","volume":"27","author":"H Ogawa","year":"2024","unstructured":"Ogawa H, Abe H, Yagi K, Seto Y, Ushiku T. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination. Gastric Cancer. 2024;27:802\u201310. https:\/\/doi.org\/10.1007\/s10120-024-01505-6.","journal-title":"Gastric Cancer"},{"key":"1803_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia K, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 2022;20:223. https:\/\/doi.org\/10.1186\/s12916-022-02421-1.","journal-title":"BMC Med"},{"key":"1803_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","volume":"36","author":"C Qi","year":"2024","unstructured":"Qi C, et al. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study. Chin J Cancer Res. 2024;36:78\u201389. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.01.08.","journal-title":"Chin J Cancer Res"},{"key":"1803_CR22","doi-asserted-by":"publisher","unstructured":"Pellino A, et al. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J Pers Med. 2021;11. https:\/\/doi.org\/10.3390\/jpm11111095.","DOI":"10.3390\/jpm11111095"},{"key":"1803_CR23","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.21873\/anticanres.13919","volume":"39","author":"JH Baek","year":"2019","unstructured":"Baek JH, et al. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer. Anticancer Res. 2019;39:6973\u20139. https:\/\/doi.org\/10.21873\/anticanres.13919.","journal-title":"Anticancer Res"},{"key":"1803_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12253-015-9996-6","volume":"22","author":"YC Chen","year":"2016","unstructured":"Chen YC, et al. Clinicopathological Variation of Lauren Classification in Gastric Cancer. Pathol Oncol Res. 2016;22:197\u2013202. https:\/\/doi.org\/10.1007\/s12253-015-9996-6.","journal-title":"Pathol Oncol Res"},{"key":"1803_CR25","doi-asserted-by":"publisher","first-page":"155628","DOI":"10.1016\/j.prp.2024.155628","volume":"263","author":"M Kim","year":"2024","unstructured":"Kim M, Kang BW, Park J, Baek JH, Kim JG. Expression of claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters in East Asian patients. Pathol Res Pract. 2024;263:155628. https:\/\/doi.org\/10.1016\/j.prp.2024.155628.","journal-title":"Pathol Res Pract"},{"key":"1803_CR26","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8:100762. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100762.","journal-title":"ESMO Open"},{"key":"1803_CR27","doi-asserted-by":"publisher","first-page":"e2300543","DOI":"10.1200\/po.23.00543","volume":"8","author":"R Waters","year":"2024","unstructured":"Waters R, et al. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma. JCO Precis Oncol. 2024;8:e2300543. https:\/\/doi.org\/10.1200\/po.23.00543.","journal-title":"JCO Precis Oncol"},{"key":"1803_CR28","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","volume":"22","author":"A Arnold","year":"2020","unstructured":"Arnold A, et al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol. 2020;22:2357\u201363. https:\/\/doi.org\/10.1007\/s12094-020-02380-0.","journal-title":"Clin Transl Oncol"},{"key":"1803_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cncy.22688","volume":"131","author":"J Dai","year":"2023","unstructured":"Dai J, Zheng H, Jin J, Cheng Y, Xu H. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens. Cancer Cytopathol. 2023;131:365\u201372. https:\/\/doi.org\/10.1002\/cncy.22688.","journal-title":"Cancer Cytopathol"},{"key":"1803_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10120-014-0338-2","volume":"18","author":"T Sawada","year":"2015","unstructured":"Sawada T, et al. New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan Society for Gastroenterological Carcinogenesis G-Project committee. Gastric Cancer. 2015;18:119\u201328. https:\/\/doi.org\/10.1007\/s10120-014-0338-2.","journal-title":"Gastric Cancer"},{"key":"1803_CR31","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1200\/JCO.2025.43.16_suppl.4037","volume":"43","author":"SY Rha","year":"2025","unstructured":"Rha SY, et al. Co-expressing pattern of multiple biomakers and dynamic change of Claudin18.2 expression after systemic chemotherapy in advanced gastric cancer. J Clin Oncol. 2025;43:4037\u20134037. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4037.","journal-title":"J Clin Oncol"},{"key":"1803_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4251\/wjgo.v15.i2.343","volume":"15","author":"E Kayikcioglu","year":"2023","unstructured":"Kayikcioglu E, Y\u00fcceer RO, Cetin B, Y\u00fcceer K, Karahan N. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma. World J Gastrointest Oncol. 2023;15:343\u201351. https:\/\/doi.org\/10.4251\/wjgo.v15.i2.343.","journal-title":"World J Gastrointest Oncol"},{"key":"1803_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47178-6","volume":"13","author":"HD Kim","year":"2023","unstructured":"Kim HD, et al. Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. Sci Rep. 2023;13:20047. https:\/\/doi.org\/10.1038\/s41598-023-47178-6.","journal-title":"Sci Rep"},{"key":"1803_CR34","doi-asserted-by":"publisher","unstructured":"Liu S, et al. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression. Cell Commun Signal. 2024;22. https:\/\/doi.org\/10.1186\/s12964-023-01406-8.","DOI":"10.1186\/s12964-023-01406-8"},{"key":"1803_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/path.1922","volume":"208","author":"Y Sanada","year":"2006","unstructured":"Sanada Y, et al. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol. 2006;208:633\u201342. https:\/\/doi.org\/10.1002\/path.1922.","journal-title":"J Pathol"},{"key":"1803_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1494131","volume":"15","author":"J Wu","year":"2024","unstructured":"Wu J, et al. Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers. Front Pharmacol. 2024;15:1494131. https:\/\/doi.org\/10.3389\/fphar.2024.1494131.","journal-title":"Front Pharmacol"},{"key":"1803_CR37","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.2174\/0109298673288604240408065715","volume":"32","author":"JY Hur","year":"2025","unstructured":"Hur JY, et al. CLDN18: Clinical, Pathological, and Genetic Signatures with Drug Screening in Gastric Adenocarcinoma. Curr Med Chem. 2025;32:2409\u201321. https:\/\/doi.org\/10.2174\/0109298673288604240408065715.","journal-title":"Curr Med Chem"},{"key":"1803_CR38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.5230\/jgc.2025.25.e47","volume":"25","author":"S Ahn","year":"2025","unstructured":"Ahn S, Hwang I, Kim KM. Correlation and Overlap Between Claudin 18.2 and FGFR2b Overexpression: A Tissue Microarray Study With 1,538 Gastric Carcinomas. J Gastric Cancer. 2025;25:639\u201350. https:\/\/doi.org\/10.5230\/jgc.2025.25.e47.","journal-title":"J Gastric Cancer"},{"key":"1803_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5230\/jgc.2025.25.e2","volume":"25","author":"SM Son","year":"2025","unstructured":"Son SM, et al. Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer. J Gastric Cancer. 2025;25:303\u201317. https:\/\/doi.org\/10.5230\/jgc.2025.25.e2.","journal-title":"J Gastric Cancer"},{"key":"1803_CR40","doi-asserted-by":"publisher","first-page":"103663","DOI":"10.1016\/j.esmoop.2024.103663","volume":"9","author":"F Lordick","year":"2024","unstructured":"Lordick F, et al. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024;9:103663. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103663.","journal-title":"ESMO Open"},{"key":"1803_CR41","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27:1058\u201368. https:\/\/doi.org\/10.1007\/s10120-024-01518-1.","journal-title":"Gastric Cancer"},{"key":"1803_CR42","unstructured":"Choi E, Shin J, Ryu M-H, Kim H-D, Park YS. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer."},{"key":"1803_CR43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32:609\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005.","journal-title":"Ann Oncol"},{"key":"1803_CR44","doi-asserted-by":"publisher","unstructured":"Chen Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol. 2025;18. https:\/\/doi.org\/10.1186\/s13045-025-01698-y.","DOI":"10.1186\/s13045-025-01698-y"},{"key":"1803_CR45","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.3390\/curroncol31120572","volume":"31","author":"C Brezden-Masley","year":"2024","unstructured":"Brezden-Masley C, et al. Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma. Curr Oncol. 2024;31:7770\u201386. https:\/\/doi.org\/10.3390\/curroncol31120572.","journal-title":"Curr Oncol"},{"key":"1803_CR46","doi-asserted-by":"publisher","unstructured":"Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025;23. https:\/\/doi.org\/10.6004\/jnccn.2025.7036.","DOI":"10.6004\/jnccn.2025.7036"},{"key":"1803_CR47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00428-025-04222-2","volume":"487","author":"C Luchini","year":"2025","unstructured":"Luchini C, et al. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Virchows Arch. 2025;487:487\u201399. https:\/\/doi.org\/10.1007\/s00428-025-04222-2.","journal-title":"Virchows Arch"},{"key":"1803_CR48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5230\/jgc.2026.26.e10","volume":"26","author":"F Zhang","year":"2026","unstructured":"Zhang F, Okazaki U, Nakayama I, Shitara K. CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives. J Gastric Cancer. 2026;26:127\u201345. https:\/\/doi.org\/10.5230\/jgc.2026.26.e10.","journal-title":"J Gastric Cancer"},{"key":"1803_CR49","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati I, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer. 2019;121:257\u201363. https:\/\/doi.org\/10.1038\/s41416-019-0508-4.","journal-title":"Br J Cancer"},{"key":"1803_CR50","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde C, et al. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49:870\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyz068.","journal-title":"Jpn J Clin Oncol"},{"key":"1803_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000545769","volume":"92","author":"S K\u00f6fler","year":"2025","unstructured":"K\u00f6fler S, et al. Computer-Aided Diagnostics Helps Accurately Determine Different Expression Levels of Claudin-18.2 in Gastric Cancer. Pathobiology. 2025;92:265\u201375. https:\/\/doi.org\/10.1159\/000545769.","journal-title":"Pathobiology"},{"key":"1803_CR52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2023.02.012","volume":"185","author":"M Backman","year":"2023","unstructured":"Backman M, et al. Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer. Eur J Cancer. 2023;185:40\u201352. https:\/\/doi.org\/10.1016\/j.ejca.2023.02.012.","journal-title":"Eur J Cancer"},{"key":"1803_CR53","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1200\/JCO.2025.43.16_suppl.4047","volume":"43","author":"H-D Kim","year":"2025","unstructured":"Kim H-D, et al. Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype to guide treatment decisions in patients with gastric cancer. J Clin Oncol. 2025;43:4047\u20134047. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4047.","journal-title":"J Clin Oncol"},{"key":"1803_CR54","doi-asserted-by":"publisher","first-page":"100452","DOI":"10.1016\/j.cjac.2024.100452","volume":"52","author":"J Cai","year":"2024","unstructured":"Cai J, Chong X, Fan L, Li Q, Zhang X. A molecular beacon detects CLDN18.2 for precision medicine in gastric cancer. Chin J Anal Chem. 2024;52:100452. https:\/\/doi.org\/10.1016\/j.cjac.2024.100452.","journal-title":"Chin J Anal Chem"},{"key":"1803_CR55","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ijrobp.2025.09.022","volume":"124","author":"J Wang","year":"2026","unstructured":"Wang J, et al. Noninvasive Imaging of Claudin 18.2 Expression in Gastric Adenocarcinoma: Synthesis, Preclinical Evaluation, and Preliminary Clinical Study of a Novel [(89)Zr]Zr-DFO-NY005 Immuno-Positron Emission Tomography Tracer. Int J Radiat Oncol Biol Phys. 2026;124:541\u201351. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.022.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1803_CR56","unstructured":"Wang, Y.et al. A First-in-Human Study of [68Ga]Ga-SNA014, a Novel Nanobody PET Tracer for CLDN18.2-Expressing Solid TumorsJournal of Nuclear Medicine 66, 251042 (2025)."},{"key":"1803_CR57","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Comprehensive molecular characterization of gastric adenocarcinoma","year":"2014","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"},{"key":"1803_CR58","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41419-023-05992-w","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung cancers. Cell Death Dis. 2023;14:462. https:\/\/doi.org\/10.1038\/s41419-023-05992-w.","journal-title":"Cell Death Dis"},{"key":"1803_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012683","author":"SH Lim","year":"2025","unstructured":"Lim SH. Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-012683.","journal-title":"J Immunother Cancer"},{"key":"1803_CR60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang C, et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 2023;23:283. https:\/\/doi.org\/10.1186\/s12876-023-02924-y.","journal-title":"BMC Gastroenterol"},{"key":"1803_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030663","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: What Is Next? Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15030663.","journal-title":"Cancers (Basel)"},{"key":"1803_CR62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin H, et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol. 2025;18:62. https:\/\/doi.org\/10.1186\/s13045-025-01701-6.","journal-title":"J Hematol Oncol"},{"key":"1803_CR63","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/d41573-024-00172-7","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. FDA approves first claudin-18.2-targeted antibody for gastric cancer. Nat Rev Drug Discov. 2024;23:884. https:\/\/doi.org\/10.1038\/d41573-024-00172-7.","journal-title":"Nat Rev Drug Discov"},{"key":"1803_CR64","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2024.5424","author":"M Katoh","year":"2024","unstructured":"Katoh M, Katoh M. Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review). Int J Mol Med. 2024. https:\/\/doi.org\/10.3892\/ijmm.2024.5424.","journal-title":"Int J Mol Med"},{"key":"1803_CR65","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/d41573-023-00120-x","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. Claudin-18.2 attracts the cancer crowd. Nat Rev Drug Discov. 2023;22:683\u20136. https:\/\/doi.org\/10.1038\/d41573-023-00120-x.","journal-title":"Nat Rev Drug Discov"},{"key":"1803_CR66","doi-asserted-by":"publisher","first-page":"643872","DOI":"10.3389\/fonc.2021.643872","volume":"11","author":"BS Ungureanu","year":"2021","unstructured":"Ungureanu BS, et al. Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis. Front Oncol. 2021;11:643872. https:\/\/doi.org\/10.3389\/fonc.2021.643872.","journal-title":"Front Oncol"},{"key":"1803_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006704","author":"J Gao","year":"2023","unstructured":"Gao J. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-006704.","journal-title":"J Immunother Cancer"},{"key":"1803_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41423-021-00742-4","volume":"19","author":"LA Huppert","year":"2022","unstructured":"Huppert LA, et al. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. Cell Mol Immunol. 2022;19:33\u201345. https:\/\/doi.org\/10.1038\/s41423-021-00742-4.","journal-title":"Cell Mol Immunol"},{"key":"1803_CR69","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41:450\u201365. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.014.","journal-title":"Cancer Cell"},{"key":"1803_CR70","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.trecan.2023.07.015","volume":"9","author":"JH Kang","year":"2023","unstructured":"Kang JH, Zappasodi R. Modulating Treg stability to improve cancer immunotherapy. Trends Cancer. 2023;9:911\u201327. https:\/\/doi.org\/10.1016\/j.trecan.2023.07.015.","journal-title":"Trends Cancer"},{"key":"1803_CR71","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1158\/0008-5472.CAN-21-1203","volume":"81","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty S, Zappasodi R. To Go or Not to Go?\u2014Targeting Tregs Traveling in Tumors. Cancer Res. 2021;81:2817\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1203.","journal-title":"Cancer Res"},{"key":"1803_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132120","author":"K Zarampouka","year":"2025","unstructured":"Zarampouka K. Correlation of CLDN18.2 and Tumor Microenvironment in Gastric Cancer: A Systematic Review. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17132120.","journal-title":"Cancers (Basel)"},{"key":"1803_CR73","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41416-025-02981-y","volume":"132","author":"C Tsutsumi","year":"2025","unstructured":"Tsutsumi C, et al. Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment. Br J Cancer. 2025;132:793\u2013804. https:\/\/doi.org\/10.1038\/s41416-025-02981-y.","journal-title":"Br J Cancer"},{"key":"1803_CR74","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/2767-9764.Crc-22-0216","volume":"2","author":"H Konno","year":"2022","unstructured":"Konno H, et al. ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models. Cancer Res Commun. 2022;2:937\u201350. https:\/\/doi.org\/10.1158\/2767-9764.Crc-22-0216.","journal-title":"Cancer Res Commun"},{"key":"1803_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002548","author":"S Liu","year":"2021","unstructured":"Liu S. S100A4 enhances protumor macrophage polarization by control of PPAR-\u03b3-dependent induction of fatty acid oxidation. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002548.","journal-title":"J Immunother Cancer"},{"key":"1803_CR76","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425\u201340. https:\/\/doi.org\/10.1002\/jcp.26429.","journal-title":"J Cell Physiol"},{"key":"1803_CR77","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1146\/annurev-immunol-032414-112220","volume":"33","author":"C Varol","year":"2015","unstructured":"Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol. 2015;33:643\u201375. https:\/\/doi.org\/10.1146\/annurev-immunol-032414-112220.","journal-title":"Annu Rev Immunol"},{"key":"1803_CR78","doi-asserted-by":"publisher","first-page":"1113378","DOI":"10.3389\/fphar.2023.1113378","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang C, et al. CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy? Front Pharmacol. 2023;14:1113378. https:\/\/doi.org\/10.3389\/fphar.2023.1113378.","journal-title":"Front Pharmacol"},{"key":"1803_CR79","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22:159. https:\/\/doi.org\/10.1186\/s12943-023-01860-5.","journal-title":"Mol Cancer"},{"key":"1803_CR80","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.trecan.2025.04.012","volume":"11","author":"Z Xia","year":"2025","unstructured":"Xia Z, De Wever O. The plasticity of cancer-associated fibroblasts. Trends Cancer. 2025;11:770\u201389. https:\/\/doi.org\/10.1016\/j.trecan.2025.04.012.","journal-title":"Trends Cancer"},{"key":"1803_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia H, Chen X, Zhang L, Chen M. Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol. 2025;18:36. https:\/\/doi.org\/10.1186\/s13045-025-01688-0.","journal-title":"J Hematol Oncol"},{"key":"1803_CR82","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41586-025-09303-5","volume":"645","author":"J Heide","year":"2025","unstructured":"Heide J, et al. NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature. 2025;645:1051\u20139. https:\/\/doi.org\/10.1038\/s41586-025-09303-5.","journal-title":"Nature"},{"key":"1803_CR83","doi-asserted-by":"publisher","first-page":"110807","DOI":"10.1016\/j.intimp.2023.110807","volume":"124","author":"L Tang","year":"2023","unstructured":"Tang L, et al. Dominant negative TGF\u03b2 receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer. Int Immunopharmacol. 2023;124:110807. https:\/\/doi.org\/10.1016\/j.intimp.2023.110807.","journal-title":"Int Immunopharmacol"},{"key":"1803_CR84","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12967-024-04990-6","volume":"22","author":"N Yang","year":"2024","unstructured":"Yang N, et al. CD19\/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. J Transl Med. 2024;22:274. https:\/\/doi.org\/10.1186\/s12967-024-04990-6.","journal-title":"J Transl Med"},{"key":"1803_CR85","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174\u201386. https:\/\/doi.org\/10.1038\/s41568-019-0238-1.","journal-title":"Nat Rev Cancer"},{"key":"1803_CR86","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun R, et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer. Mol Ther. 2023;31:3193\u2013209. https:\/\/doi.org\/10.1016\/j.ymthe.2023.09.010.","journal-title":"Mol Ther"},{"key":"1803_CR87","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-021-04084-z","volume":"600","author":"D Diwanji","year":"2021","unstructured":"Diwanji D, et al. Structures of the HER2-HER3-NRG1\u03b2 complex reveal a dynamic dimer interface. Nature. 2021;600:339\u201343. https:\/\/doi.org\/10.1038\/s41586-021-04084-z.","journal-title":"Nature"},{"key":"1803_CR88","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","volume":"39","author":"AB Hanker","year":"2021","unstructured":"Hanker AB, et al. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell. 2021;39:1099\u2013e11141098. https:\/\/doi.org\/10.1016\/j.ccell.2021.06.001.","journal-title":"Cancer Cell"},{"key":"1803_CR89","doi-asserted-by":"publisher","first-page":"1132319","DOI":"10.3389\/fonc.2023.1132319","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, et al. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. Front Oncol. 2023;13:1132319. https:\/\/doi.org\/10.3389\/fonc.2023.1132319.","journal-title":"Front Oncol"},{"key":"1803_CR90","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/s1470-2045(23)00676-9","volume":"25","author":"IM Browne","year":"2024","unstructured":"Browne IM, Andr\u00e9 F, Chandarlapaty S, Carey LA, Turner NC. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024;25:e139\u201351. https:\/\/doi.org\/10.1016\/s1470-2045(23)00676-9.","journal-title":"Lancet Oncol"},{"key":"1803_CR91","doi-asserted-by":"publisher","first-page":"e2415322","DOI":"10.1002\/adma.202415322","volume":"37","author":"L Yin","year":"2025","unstructured":"Yin L, et al. PSMA-Targeted Nanoparticles with PI3K\/mTOR Dual Inhibitor Downregulate P-Glycoprotein and Inactivate Myeloid-Derived Suppressor Cells for Enhanced Chemotherapy and Immunotherapy in Prostate Cancer. Adv Mater. 2025;37:e2415322. https:\/\/doi.org\/10.1002\/adma.202415322.","journal-title":"Adv Mater"},{"key":"1803_CR92","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41419-024-06848-7","volume":"15","author":"YN Zheng","year":"2024","unstructured":"Zheng YN, et al. Selective PI3K\u03b4 inhibitor TYM-3-98 suppresses AKT\/mTOR\/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer. Cell Death Dis. 2024;15:474. https:\/\/doi.org\/10.1038\/s41419-024-06848-7.","journal-title":"Cell Death Dis"},{"key":"1803_CR93","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/jci39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420\u20138. https:\/\/doi.org\/10.1172\/jci39104.","journal-title":"J Clin Invest"},{"key":"1803_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112767","author":"Y Hao","year":"2019","unstructured":"Hao Y, Baker D, Ten Dijke P. TGF-\u03b2-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20112767.","journal-title":"Int J Mol Sci"},{"key":"1803_CR95","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/ncb1998","volume":"11","author":"U Wellner","year":"2009","unstructured":"Wellner U, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11:1487\u201395. https:\/\/doi.org\/10.1038\/ncb1998.","journal-title":"Nat Cell Biol"},{"key":"1803_CR96","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.2174\/0929867326666191113113110","volume":"27","author":"P Yang","year":"2020","unstructured":"Yang P, Hu Y, Zhou Q. The CXCL12-CXCR4 Signaling Axis Plays a Key Role in Cancer Metastasis and is a Potential Target for Developing Novel Therapeutics against Metastatic Cancer. Curr Med Chem. 2020;27:5543\u201361. https:\/\/doi.org\/10.2174\/0929867326666191113113110.","journal-title":"Curr Med Chem"},{"key":"1803_CR97","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41590-023-01443-y","volume":"24","author":"MM Steele","year":"2023","unstructured":"Steele MM, et al. T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control. Nat Immunol. 2023;24:664\u201375. https:\/\/doi.org\/10.1038\/s41590-023-01443-y.","journal-title":"Nat Immunol"},{"key":"1803_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006808","author":"J Xu","year":"2023","unstructured":"Xu J. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-006808.","journal-title":"J Immunother Cancer"},{"key":"1803_CR99","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1186\/s12967-025-06776-w","volume":"23","author":"Z Zeng","year":"2025","unstructured":"Zeng Z, et al. MRO\/HNRNPU\/CCL5 feedback loop amplifies M2 macrophage and breast cancer cell crosstalk to drive progression. J Transl Med. 2025;23:920. https:\/\/doi.org\/10.1186\/s12967-025-06776-w.","journal-title":"J Transl Med"},{"key":"1803_CR100","doi-asserted-by":"publisher","first-page":"107893","DOI":"10.1016\/j.phrs.2025.107893","volume":"219","author":"J Gao","year":"2025","unstructured":"Gao J, et al. Unveiling the role of c-Met: A promising target for cardiovascular disease. Pharmacol Res. 2025;219:107893. https:\/\/doi.org\/10.1016\/j.phrs.2025.107893.","journal-title":"Pharmacol Res"},{"key":"1803_CR101","doi-asserted-by":"publisher","first-page":"155379","DOI":"10.1016\/j.phymed.2024.155379","volume":"128","author":"CD Mohan","year":"2024","unstructured":"Mohan CD, et al. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy. Phytomedicine. 2024;128:155379. https:\/\/doi.org\/10.1016\/j.phymed.2024.155379.","journal-title":"Phytomedicine"},{"key":"1803_CR102","doi-asserted-by":"publisher","unstructured":"Yang Q, Han X. Prognostic value of c-MET protein expression in gastric cancer patients: a systematic review and meta-analysis. Biomarkers. 2025;1\u201310. https:\/\/doi.org\/10.1080\/1354750x.2025.2544556.","DOI":"10.1080\/1354750x.2025.2544556"},{"key":"1803_CR103","doi-asserted-by":"publisher","unstructured":"Pereira MA et al. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients. Med Sci (Basel) 10. https:\/\/doi.org\/10.3390\/medsci10010004 (2021).","DOI":"10.3390\/medsci10010004"},{"key":"1803_CR104","doi-asserted-by":"publisher","first-page":"154699","DOI":"10.1016\/j.prp.2023.154699","volume":"248","author":"D Tao","year":"2023","unstructured":"Tao D, et al. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer. Pathol Res Pract. 2023;248:154699. https:\/\/doi.org\/10.1016\/j.prp.2023.154699.","journal-title":"Pathol Res Pract"},{"key":"1803_CR105","doi-asserted-by":"publisher","unstructured":"Carpenter J, et al. Assembly and organization of the N-terminal region of mucin MUC5AC: Indications for structural and functional distinction from MUC5B. Proc Natl Acad Sci U S A. 2021;118. https:\/\/doi.org\/10.1073\/pnas.2104490118.","DOI":"10.1073\/pnas.2104490118"},{"key":"1803_CR106","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1038\/s41467-022-33097-z","volume":"13","author":"SP Sajuthi","year":"2022","unstructured":"Sajuthi SP, et al. Author Correction: Nasal airway transcriptome-wide association study of asthma reveals genetically driven mucus pathobiology. Nat Commun. 2022;13:5806. https:\/\/doi.org\/10.1038\/s41467-022-33097-z.","journal-title":"Nat Commun"},{"key":"1803_CR107","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41434-025-00564-3","volume":"32","author":"S Kumar","year":"2025","unstructured":"Kumar S, Corkran M, Cheema Y, Scull MA, Duncan G. A. AAV-mediated MUC5AC siRNA delivery to prevent mucociliary dysfunction in asthma. Gene Ther. 2025;32:508\u201316. https:\/\/doi.org\/10.1038\/s41434-025-00564-3.","journal-title":"Gene Ther"},{"key":"1803_CR108","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s2468-1253(24)00390-x","volume":"10","author":"MF Neurath","year":"2025","unstructured":"Neurath MF, Artis D, Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer. Lancet Gastroenterol Hepatol. 2025;10:573\u201392. https:\/\/doi.org\/10.1016\/s2468-1253(24)00390-x.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1803_CR109","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40168-023-01534-w","volume":"11","author":"B Oosterlinck","year":"2023","unstructured":"Oosterlinck B, et al. Mucin-microbiome signatures shape the tumor microenvironment in gastric cancer. Microbiome. 2023;11:86. https:\/\/doi.org\/10.1186\/s40168-023-01534-w.","journal-title":"Microbiome"},{"key":"1803_CR110","doi-asserted-by":"publisher","first-page":"916933","DOI":"10.3389\/fimmu.2022.916933","volume":"13","author":"W Hu","year":"2022","unstructured":"Hu W, et al. Endotoxins Induced ECM-Receptor Interaction Pathway Signal Effect on the Function of MUC2 in Caco2\/HT29 Co-Culture Cells. Front Immunol. 2022;13:916933. https:\/\/doi.org\/10.3389\/fimmu.2022.916933.","journal-title":"Front Immunol"},{"key":"1803_CR111","doi-asserted-by":"publisher","first-page":"103751","DOI":"10.1016\/j.ebiom.2021.103751","volume":"74","author":"D Yao","year":"2021","unstructured":"Yao D, Dai W, Dong M, Dai C, Wu S. MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis. EBioMedicine. 2021;74:103751. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103751.","journal-title":"EBioMedicine"},{"key":"1803_CR112","doi-asserted-by":"publisher","first-page":"2542385","DOI":"10.1080\/19490976.2025.2542385","volume":"17","author":"H Gorman","year":"2025","unstructured":"Gorman H, et al. Using MUC2 mucin producing tumorigenic human goblet-like cells to uncover functional properties of the mucus barrier. Gut Microbes. 2025;17:2542385. https:\/\/doi.org\/10.1080\/19490976.2025.2542385.","journal-title":"Gut Microbes"},{"key":"1803_CR113","doi-asserted-by":"publisher","first-page":"6566","DOI":"10.1038\/sj.onc.1210479","volume":"26","author":"A Vincent","year":"2007","unstructured":"Vincent A, et al. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene. 2007;26:6566\u201376. https:\/\/doi.org\/10.1038\/sj.onc.1210479.","journal-title":"Oncogene"},{"key":"1803_CR114","doi-asserted-by":"publisher","unstructured":"Bai Y, et al. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. J Immunother Cancer. 2022;10. https:\/\/doi.org\/10.1136\/jitc-2021-004080.","DOI":"10.1136\/jitc-2021-004080"},{"key":"1803_CR115","doi-asserted-by":"publisher","unstructured":"Li X, et al. A novel biomarker associated with EBV infection improves response prediction of immunotherapy in gastric cancer. J Transl Med. 2024;22. https:\/\/doi.org\/10.1186\/s12967-024-04859-8.","DOI":"10.1186\/s12967-024-04859-8"},{"key":"1803_CR116","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.critrevonc.2019.01.014","volume":"135","author":"M Dong","year":"2019","unstructured":"Dong M, Chen JN, Huang JT, Gong LP, Shao CK. The roles of EBV-encoded microRNAs in EBV-associated tumors. Crit Rev Oncol Hematol. 2019;135:30\u20138. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.01.014.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1803_CR117","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/rmv.582","volume":"18","author":"H Kimura","year":"2008","unstructured":"Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol. 2008;18:305\u201319. https:\/\/doi.org\/10.1002\/rmv.582.","journal-title":"Rev Med Virol"},{"key":"1803_CR118","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3760\/cma.j.cn112140-20210618-00513","volume":"59","author":"[Experts consensus on diagnosis and treatment of","year":"2021","unstructured":"[Experts consensus on diagnosis and treatment of. Epstein-Barr virus infection-related diseases in children]. Zhonghua Er Ke Za Zhi. 2021;59:905\u201311. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20210618-00513.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"1803_CR119","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024;21:675\u2013700. https:\/\/doi.org\/10.1038\/s41571-024-00924-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"1803_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40715-x","volume":"14","author":"LJ Dai","year":"2023","unstructured":"Dai LJ, et al. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer. Nat Commun. 2023;14:5112. https:\/\/doi.org\/10.1038\/s41467-023-40715-x.","journal-title":"Nat Commun"},{"key":"1803_CR121","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.asjsur.2022.06.039","volume":"46","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Clinicopathologic significance of Her-2 and P(53) expressions in gastric cancer. Asian J Surg. 2023;46:526\u201331. https:\/\/doi.org\/10.1016\/j.asjsur.2022.06.039.","journal-title":"Asian J Surg"},{"key":"1803_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103864","volume":"180","author":"A Aisa","year":"2022","unstructured":"Aisa A, Weng S, Li X, Zhang D, Yuan Y. Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer. Crit Rev Oncol Hematol. 2022;180:103864. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103864.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1803_CR123","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy269.101","volume":"29","author":"D Moran","year":"2018","unstructured":"Moran D, Maurus D, Rohde C, Arozullah A. Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples. Ann Oncol. 2018;29:viii32. https:\/\/doi.org\/10.1093\/annonc\/mdy269.101.","journal-title":"Ann Oncol"},{"key":"1803_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2.","journal-title":"Mol Cancer"},{"key":"1803_CR125","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287\u2013305. https:\/\/doi.org\/10.1038\/s41571-022-00601-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"1803_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist Updat. 2023;66:100907. https:\/\/doi.org\/10.1016\/j.drup.2022.100907.","journal-title":"Drug Resist Updat"},{"key":"1803_CR127","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume":"1248","author":"L Ai","year":"2020","unstructured":"Ai L, Xu A, Xu J. Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33\u201359. https:\/\/doi.org\/10.1007\/978-981-15-3266-5_3.","journal-title":"Adv Exp Med Biol"},{"key":"1803_CR128","doi-asserted-by":"publisher","first-page":"1296341","DOI":"10.3389\/fimmu.2023.1296341","volume":"14","author":"A Parvez","year":"2023","unstructured":"Parvez A, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Immunol. 2023;14:1296341. https:\/\/doi.org\/10.3389\/fimmu.2023.1296341.","journal-title":"Front Immunol"},{"key":"1803_CR129","doi-asserted-by":"publisher","first-page":"e16094","DOI":"10.1200\/JCO.2025.43.16_suppl.e16094","volume":"43","author":"DR Castillo","year":"2025","unstructured":"Castillo DR, et al. Association of Claudin18.2 expression, PD-L1, and prognostic implications in gastric and gastroesophageal junction cancers. J Clin Oncol. 2025;43:e16094\u201316094. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e16094.","journal-title":"J Clin Oncol"},{"key":"1803_CR130","doi-asserted-by":"publisher","unstructured":"Kwak Y, et al. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. Oncologist. 2025;30. https:\/\/doi.org\/10.1093\/oncolo\/oyae238.","DOI":"10.1093\/oncolo\/oyae238"},{"key":"1803_CR131","unstructured":"Li J, Shen R-HXL. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer. (2025)."},{"key":"1803_CR132","unstructured":"al. Q-YL. e. Interpretation of the key updates in the 2025 edition of the Chinese Society of Clinical Oncology(CSCO) guidelines for the diagnosis and treatment of gastric cancer. J Dig Oncol 17 (2025)."},{"key":"1803_CR133","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"1803_CR134","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/s0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(23)00620-7.","journal-title":"Lancet"},{"key":"1803_CR135","doi-asserted-by":"publisher","first-page":"175628482412970","DOI":"10.1177\/17562848241297052","volume":"17","author":"J Lei","year":"2024","unstructured":"Lei J, et al. First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis. Ther Adv Gastroenterol. 2024;17:17562848241297052. https:\/\/doi.org\/10.1177\/17562848241297052.","journal-title":"Ther Adv Gastroenterol"},{"key":"1803_CR136","doi-asserted-by":"publisher","unstructured":"Grewal US, Brown TJ. New tool in the toolbox: patient selection for zolbetuximab in advanced treatment-na\u00efve gastric\/gastroesophageal junction adenocarcinoma. Oncologist. 2025;30. https:\/\/doi.org\/10.1093\/oncolo\/oyaf185.","DOI":"10.1093\/oncolo\/oyaf185"},{"key":"1803_CR137","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s0140-6736(10)61121-x","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(10)61121-x.","journal-title":"Lancet"},{"key":"1803_CR138","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13561-024-00571-x","volume":"14","author":"S Kaveh","year":"2024","unstructured":"Kaveh S, Ghadimi N, Alvar Z, Roudini A, K., Daroudi R. Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis. Health Econ Rev. 2024;14:89. https:\/\/doi.org\/10.1186\/s13561-024-00571-x.","journal-title":"Health Econ Rev"},{"key":"1803_CR139","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/bjc.2011.390","volume":"105","author":"T Shiroiwa","year":"2011","unstructured":"Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011;105:1273\u20138. https:\/\/doi.org\/10.1038\/bjc.2011.390.","journal-title":"Br J Cancer"},{"key":"1803_CR140","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/s0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197\u2013208. https:\/\/doi.org\/10.1016\/s0140-6736(23)02033-0.","journal-title":"Lancet"},{"key":"1803_CR141","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1200\/JCO.2025.43.4_suppl.354","volume":"43","author":"SY Rha","year":"2025","unstructured":"Rha SY, et al. Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma in the KEYNOTE-811 trial. J Clin Oncol. 2025;43:354\u2013354. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.354.","journal-title":"J Clin Oncol"},{"key":"1803_CR142","doi-asserted-by":"publisher","first-page":"105542","DOI":"10.1016\/j.esmoop.2025.105542","volume":"10","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, et al. Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial. ESMO Open. 2025;10:105542. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105542.","journal-title":"ESMO Open"},{"key":"1803_CR143","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"1803_CR144","doi-asserted-by":"crossref","unstructured":"Rogers JE, Ajani JA. How do we improve chemoimmunotherapy in gastroesophageal adenocarcinoma? AME Clinical Trials Review; Vol 3 (February 25, 2025): AME Clinical Trials Review (2025).","DOI":"10.21037\/actr-24-137"},{"key":"1803_CR145","doi-asserted-by":"publisher","first-page":"10961","DOI":"10.1038\/s41598-025-95501-0","volume":"15","author":"T Arigami","year":"2025","unstructured":"Arigami T, et al. Prognostic impact of clinical trial eligibility in patients with advanced gastric cancer. Sci Rep. 2025;15:10961. https:\/\/doi.org\/10.1038\/s41598-025-95501-0.","journal-title":"Sci Rep"},{"key":"1803_CR146","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10120-025-01634-6","volume":"28","author":"D Lin","year":"2025","unstructured":"Lin D, et al. Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results. Gastric Cancer. 2025;28:935\u201344. https:\/\/doi.org\/10.1007\/s10120-025-01634-6.","journal-title":"Gastric Cancer"},{"key":"1803_CR147","doi-asserted-by":"publisher","first-page":"9651","DOI":"10.1038\/s41467-025-65148-6","volume":"16","author":"EJ Carstens","year":"2025","unstructured":"Carstens EJ, et al. Modeling and addressing on-target\/off-tumor toxicity of claudin 18.2 targeted immunotherapies. Nat Commun. 2025;16:9651. https:\/\/doi.org\/10.1038\/s41467-025-65148-6.","journal-title":"Nat Commun"},{"key":"1803_CR148","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/14712598.2026.2617271","volume":"26","author":"K Yamamoto","year":"2026","unstructured":"Yamamoto K, Nakayama I, Shitara K. Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents. Expert Opin Biol Ther. 2026;26:65\u201380. https:\/\/doi.org\/10.1080\/14712598.2026.2617271.","journal-title":"Expert Opin Biol Ther"},{"key":"1803_CR149","doi-asserted-by":"publisher","first-page":"115521","DOI":"10.1016\/j.ejca.2025.115521","volume":"224","author":"NM Rosanu","year":"2025","unstructured":"Rosanu NM, Gervaso L, Cella CA, Fazio N. Navigating the clinical challenges of zolbetuximab in patients with claudin positive advanced gastric cancer. Eur J Cancer. 2025;224:115521. https:\/\/doi.org\/10.1016\/j.ejca.2025.115521.","journal-title":"Eur J Cancer"},{"key":"1803_CR150","doi-asserted-by":"publisher","first-page":"103168","DOI":"10.1016\/j.cpcardiol.2025.103168","volume":"50","author":"RP Pamungkas","year":"2025","unstructured":"Pamungkas RP, Pratiwi L, Sutanto H. HER2-targeted therapies and cardiotoxicity: From major concern to manageable risk. Curr Probl Cardiol. 2025;50:103168. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103168.","journal-title":"Curr Probl Cardiol"},{"key":"1803_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-021-06469-0","volume":"194","author":"EA Perez","year":"2022","unstructured":"Perez EA, et al. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Res Treat. 2022;194:1\u201311. https:\/\/doi.org\/10.1007\/s10549-021-06469-0.","journal-title":"Breast Cancer Res Treat"},{"key":"1803_CR152","doi-asserted-by":"publisher","first-page":"1288362","DOI":"10.3389\/fphar.2024.1288362","volume":"15","author":"Y Bao","year":"2024","unstructured":"Bao Y, et al. Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS). Front Pharmacol. 2024;15:1288362. https:\/\/doi.org\/10.3389\/fphar.2024.1288362.","journal-title":"Front Pharmacol"},{"key":"1803_CR153","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8:262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6.","journal-title":"Signal Transduct Target Ther"},{"key":"1803_CR154","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5:1008\u201319. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393.","journal-title":"JAMA Oncol"},{"key":"1803_CR155","doi-asserted-by":"publisher","first-page":"1519082","DOI":"10.3389\/fphar.2025.1519082","volume":"16","author":"T Yan","year":"2025","unstructured":"Yan T, et al. Immune-related adverse events with PD-1\/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients. Front Pharmacol. 2025;16:1519082. https:\/\/doi.org\/10.3389\/fphar.2025.1519082.","journal-title":"Front Pharmacol"},{"key":"1803_CR156","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","volume":"4","author":"S Zinn","year":"2023","unstructured":"Zinn S, et al. Advances in antibody-based therapy in oncology. Nat Cancer. 2023;4:165\u201380. https:\/\/doi.org\/10.1038\/s43018-023-00516-z.","journal-title":"Nat Cancer"},{"key":"1803_CR157","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"1803_CR158","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1056\/NEJMe2411494","volume":"391","author":"EJ Rubin","year":"2024","unstructured":"Rubin EJ, Yeku OO, Morrissey S. NEJM at ESMO - Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med. 2024;391:e26. https:\/\/doi.org\/10.1056\/NEJMe2411494.","journal-title":"N Engl J Med"},{"key":"1803_CR159","doi-asserted-by":"publisher","first-page":"e75206","DOI":"10.7759\/cureus.75206","volume":"16","author":"A Samanta","year":"2024","unstructured":"Samanta A, Ghosh A, Sarma M. Zolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature. Cureus. 2024;16:e75206. https:\/\/doi.org\/10.7759\/cureus.75206.","journal-title":"Cureus"},{"key":"1803_CR160","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara K, et al. Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med. 2024;391:1159\u201362. https:\/\/doi.org\/10.1056\/NEJMc2409512.","journal-title":"N Engl J Med"},{"key":"1803_CR161","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.Ccr-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-1547.","journal-title":"Clin Cancer Res"},{"key":"1803_CR162","doi-asserted-by":"publisher","first-page":"217362","DOI":"10.1016\/j.canlet.2024.217362","volume":"611","author":"A Tojjari","year":"2024","unstructured":"Tojjari A, Idrissi YA, Saeed A. Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2. Cancer Lett. 2024;611:217362. https:\/\/doi.org\/10.1016\/j.canlet.2024.217362.","journal-title":"Cancer Lett"},{"key":"1803_CR163","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40265-024-02056-x","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ, Zolbetuximab. First Approval Drugs. 2024;84:977\u201383. https:\/\/doi.org\/10.1007\/s40265-024-02056-x.","journal-title":"First Approval Drugs"},{"key":"1803_CR164","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jphs.2024.04.004","volume":"155","author":"T Nishibata","year":"2024","unstructured":"Nishibata T, et al. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models. J Pharmacol Sci. 2024;155:84\u201393. https:\/\/doi.org\/10.1016\/j.jphs.2024.04.004.","journal-title":"J Pharmacol Sci"},{"key":"1803_CR165","doi-asserted-by":"publisher","first-page":"1258347","DOI":"10.3389\/fonc.2023.1258347","volume":"13","author":"Z Liang","year":"2023","unstructured":"Liang Z, et al. Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials. Front Oncol. 2023;13:1258347. https:\/\/doi.org\/10.3389\/fonc.2023.1258347.","journal-title":"Front Oncol"},{"key":"1803_CR166","doi-asserted-by":"publisher","first-page":"100206","DOI":"10.1016\/j.esmogo.2025.100206","volume":"9","author":"K Yamamoto","year":"2025","unstructured":"Yamamoto K, et al. Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer. ESMO Gastrointest Oncol. 2025;9:100206. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100206.","journal-title":"ESMO Gastrointest Oncol"},{"key":"1803_CR167","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.Ccr-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, et al. Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2023;29:3882\u201391. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-0204.","journal-title":"Clin Cancer Res"},{"key":"1803_CR168","doi-asserted-by":"publisher","unstructured":"Cao W, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10. https:\/\/doi.org\/10.1186\/s40364-022-00385-1.","DOI":"10.1186\/s40364-022-00385-1"},{"key":"1803_CR169","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10120-025-01607-9","volume":"28","author":"Y Sugiyama","year":"2025","unstructured":"Sugiyama Y, et al. Zolbetuximab-related gastritis: a case report of the patient with prolonged gastrointestinal symptoms. Gastric Cancer. 2025;28:705\u201311. https:\/\/doi.org\/10.1007\/s10120-025-01607-9.","journal-title":"Gastric Cancer"},{"key":"1803_CR170","doi-asserted-by":"publisher","unstructured":"Poniewierska-Baran A, Plewa P, \u017babicka Z, Pawlik A. Claudin18.2 as a Promising Therapeutic Target in Gastric Cancer. Cells. 2025;14. https:\/\/doi.org\/10.3390\/cells14161285.","DOI":"10.3390\/cells14161285"},{"key":"1803_CR171","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2025.43.16_suppl.4032","volume":"43","author":"J Gong","year":"2025","unstructured":"Gong J, et al. First-line osemitamab (TST001) plus nivolumab and CAPOX for advanced G\/GEJ cancer (TranStar102): Updated results of cohort G from a phase I\/IIa study. J Clin Oncol. 2025;43:4032\u20134032. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4032.","journal-title":"J Clin Oncol"},{"key":"1803_CR172","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.2024.42.16_suppl.4048","volume":"42","author":"X Zhang","year":"2024","unstructured":"Zhang X, et al. First-line osemitamab (TST001) plus nivolumab and capox for advanced g\/GEJ cancer (TranStar102): Results of cohort G from a phase I\/IIa study. J Clin Oncol. 2024;42:4048\u20134048. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4048.","journal-title":"J Clin Oncol"},{"key":"1803_CR173","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1200\/JCO.2023.41.16_suppl.4046","volume":"41","author":"L Shen","year":"2023","unstructured":"Shen L, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G\/GEJ cancer: Updated data of cohort C from a phase I\/IIa, multi-center study (TranStar102\/TST001-1002). J Clin Oncol. 2023;41:4046\u20134046. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4046.","journal-title":"J Clin Oncol"},{"key":"1803_CR174","doi-asserted-by":"publisher","unstructured":"Qian X, et al. 1560P Osemitamab (TST001): An ADCC enhanced humanized anti-CLDN18.2 mab, demonstrated improved efficacy in combination with anti-PD-L1\/PD-1 mab and oxaliplatin\/5-FU in preclinical tumor models. Ann Oncol. 2023;34. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1472.","DOI":"10.1016\/j.annonc.2023.09.1472"},{"key":"1803_CR175","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2023.41.4_suppl.798","volume":"41","author":"J Huang","year":"2023","unstructured":"Huang J, et al. Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial. J Clin Oncol. 2023;41:798\u2013798. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.798.","journal-title":"J Clin Oncol"},{"key":"1803_CR176","doi-asserted-by":"publisher","unstructured":"Konno H et al. Abstract 1203: ZL-1211 exhibits broad anti-tumor activity in CLDN18.2 high- and low-expressing models. Cancer Research 81, 1203\u20131203. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-1203 (2021).","DOI":"10.1158\/1538-7445.AM2021-1203"},{"key":"1803_CR177","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1200\/JCO.2025.43.16_suppl.4044","volume":"43","author":"M Zhang","year":"2025","unstructured":"Zhang M, et al. Second-line ASKB589 plus chemotherapy for advanced gastric or gastroesophageal cancers: Results from cohort 5 of a phase I\/II study. J Clin Oncol. 2025;43:4044\u20134044. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4044.","journal-title":"J Clin Oncol"},{"key":"1803_CR178","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2025.43.4_suppl.454","volume":"43","author":"Z Peng","year":"2025","unstructured":"Peng Z, et al. Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric\/gastro-esophageal junction (G\/GEJ) adenocarcinoma from a phase Ib\/II study. J Clin Oncol. 2025;43:454\u2013454. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.454.","journal-title":"J Clin Oncol"},{"key":"1803_CR179","doi-asserted-by":"publisher","first-page":"TPS504","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS504","volume":"43","author":"M Okunaka","year":"2025","unstructured":"Okunaka M, et al. A randomized phase II clinical trial evaluating the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with HER2-negative and CLDN18.2-positive unresectable advanced or recurrent gastric, gastroesophageal junction cancer or esophageal adenocarcinoma (GENTLE-Z). J Clin Oncol. 2025;43:TPS504\u2013504. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.TPS504.","journal-title":"J Clin Oncol"},{"key":"1803_CR180","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1200\/JCO.2023.41.16_suppl.2537","volume":"41","author":"S Sharma","year":"2023","unstructured":"Sharma S, et al. Preliminary results of a phase 1\/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors. J Clin Oncol. 2023;41:2537\u20132537. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2537.","journal-title":"J Clin Oncol"},{"key":"1803_CR181","doi-asserted-by":"publisher","first-page":"TPS4173","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4173","volume":"41","author":"K Shitara","year":"2023","unstructured":"Shitara K, et al. Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas. J Clin Oncol. 2023;41:TPS4173\u20134173. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS4173.","journal-title":"J Clin Oncol"},{"key":"1803_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04306-9","author":"K Shitara","year":"2026","unstructured":"Shitara K, et al. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04306-9.","journal-title":"Nat Med"},{"key":"1803_CR183","doi-asserted-by":"publisher","first-page":"405736","DOI":"10.1200\/JCO.2023.41.36_suppl.405736","volume":"41","author":"R-h Xu","year":"2023","unstructured":"Xu R-h, et al. Zolbetuximab\u2009+\u2009CAPOX in 1L claudin-18.2+ (CLDN18.2+)\/HER2\u2009\u2013\u2009locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Primary phase 3 results from GLOW. J Clin Oncol. 2023;41:405736\u2013405736. https:\/\/doi.org\/10.1200\/JCO.2023.41.36_suppl.405736.","journal-title":"J Clin Oncol"},{"key":"1803_CR184","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/JCO.2023.41.4_suppl.391","volume":"41","author":"J Li","year":"2023","unstructured":"Li J, et al. A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors. J Clin Oncol. 2023;41:391\u2013391. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.391.","journal-title":"J Clin Oncol"},{"key":"1803_CR185","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO.2023.41.4_suppl.466","volume":"41","author":"DM Moran","year":"2023","unstructured":"Moran DM, et al. Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G\/GEJa) treated with zolbetuximab. J Clin Oncol. 2023;41:466\u2013466. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.466.","journal-title":"J Clin Oncol"},{"key":"1803_CR186","doi-asserted-by":"publisher","unstructured":"Park W et al. Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study. J Clin Oncol 40, TPS4186\u20134186, https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS4186","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4186"},{"key":"1803_CR187","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","volume":"25","author":"AC Chan","year":"2025","unstructured":"Chan AC, Martyn GD, Carter PJ. Fifty years of monoclonals: the past, present and future of antibody therapeutics. Nat Rev Immunol. 2025;25:745\u201365. https:\/\/doi.org\/10.1038\/s41577-025-01207-9.","journal-title":"Nat Rev Immunol"},{"key":"1803_CR188","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.nbt.2011.03.021","volume":"28","author":"V Pillay","year":"2011","unstructured":"Pillay V, Gan HK, Scott AM. Antibodies in oncology. N Biotechnol. 2011;28:518\u201329. https:\/\/doi.org\/10.1016\/j.nbt.2011.03.021.","journal-title":"N Biotechnol"},{"key":"1803_CR189","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","volume":"111","author":"N Ferri","year":"2016","unstructured":"Ferri N, et al. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2016.07.015.","journal-title":"Pharmacol Res"},{"key":"1803_CR190","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","volume":"167","author":"SS Hosseini","year":"2021","unstructured":"Hosseini SS, et al. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. Int J Biol Macromol. 2021;167:1030\u201347. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.11.058.","journal-title":"Int J Biol Macromol"},{"key":"1803_CR191","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276. https:\/\/doi.org\/10.3389\/fimmu.2022.1035276.","journal-title":"Front Immunol"},{"key":"1803_CR192","doi-asserted-by":"publisher","first-page":"1020003","DOI":"10.3389\/fimmu.2022.1020003","volume":"13","author":"J Kang","year":"2022","unstructured":"Kang J, Sun T, Zhang Y. Immunotherapeutic progress and application of bispecific antibody in cancer. Front Immunol. 2022;13:1020003. https:\/\/doi.org\/10.3389\/fimmu.2022.1020003.","journal-title":"Front Immunol"},{"key":"1803_CR193","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23:301\u201319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6.","journal-title":"Nat Rev Drug Discov"},{"key":"1803_CR194","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/s0140-6736(23)00521-4","volume":"402","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402:142\u201358. https:\/\/doi.org\/10.1016\/s0140-6736(23)00521-4.","journal-title":"Lancet"},{"key":"1803_CR195","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2023.06.037","volume":"165","author":"Y Xu","year":"2023","unstructured":"Xu Y, et al. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. Gastroenterology. 2023;165:1219\u201332. https:\/\/doi.org\/10.1053\/j.gastro.2023.06.037.","journal-title":"Gastroenterology"},{"key":"1803_CR196","doi-asserted-by":"publisher","first-page":"152283","DOI":"10.1016\/j.imbio.2022.152283","volume":"227","author":"G Xu","year":"2022","unstructured":"Xu G, et al. Preclinical characterization of a Fab-like CD3\/CLDN18.2 XFab\u00ae bispecific antibody against solid tumors. Immunobiology. 2022;227:152283. https:\/\/doi.org\/10.1016\/j.imbio.2022.152283.","journal-title":"Immunobiology"},{"key":"1803_CR197","doi-asserted-by":"publisher","unstructured":"Gong J et al. Safety results of Q-1802, a Claudin18.2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study. J Clin Oncol 40, 2568\u20132568, https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2568","DOI":"10.1200\/JCO.2022.40.16_suppl.2568"},{"key":"1803_CR198","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/JCO.2023.41.4_suppl.382","volume":"41","author":"W Yk","year":"2023","unstructured":"Yk W, et al. Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. J Clin Oncol. 2023;41:382\u2013382. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.382.","journal-title":"J Clin Oncol"},{"key":"1803_CR199","doi-asserted-by":"publisher","unstructured":"Wang Y, Gong J, Qu X, Shen L. 1500 A phase II trial of bispecific antibody Q-1802 in patients with relapsed or refractory solid tumors. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1500.","DOI":"10.1136\/jitc-2024-SITC2024.1500"},{"key":"1803_CR200","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2025.43.16_suppl.2527","volume":"43","author":"Y Wang","year":"2025","unstructured":"Wang Y, et al. Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study. J Clin Oncol. 2025;43:2527\u20132527. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2527.","journal-title":"J Clin Oncol"},{"key":"1803_CR201","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jnci\/djy134","volume":"111","author":"H Jiang","year":"2019","unstructured":"Jiang H, et al. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. J Natl Cancer Inst. 2019;111:409\u201318. https:\/\/doi.org\/10.1093\/jnci\/djy134.","journal-title":"J Natl Cancer Inst"},{"key":"1803_CR202","doi-asserted-by":"publisher","unstructured":"Nakazawa T, et al. Abstract 2962: ASP2138, a novel 2\u2009+\u20091 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models. Cancer Res. 2023;83(2962\u20132962). https:\/\/doi.org\/10.1158\/1538-7445.AM2023-2962.","DOI":"10.1158\/1538-7445.AM2023-2962"},{"key":"1803_CR203","doi-asserted-by":"publisher","unstructured":"Li J et al. Abstract 4260: PT886, an anti-claudin18.2\/anti-CD47 bispecific antibody constructed with the PACbody\u08ea and SPECpair\u08ea technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model. Cancer Research 82, 4260\u20134260. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-4260 (2022).","DOI":"10.1158\/1538-7445.AM2022-4260"},{"key":"1803_CR204","doi-asserted-by":"publisher","first-page":"S933","DOI":"10.1016\/j.annonc.2024.08.1594","volume":"35","author":"MJ Overman","year":"2024","unstructured":"Overman MJ, et al. 1531TiP TWINPEAK phase I\/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and\/or pembrolizumab in gastric\/GEJ-carcinomas or PDAC. Ann Oncol. 2024;35:S933\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1594.","journal-title":"Ann Oncol"},{"key":"1803_CR205","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.4110\/in.2022.22.e4","volume":"22","author":"D Moon","year":"2022","unstructured":"Moon D, Tae N, Park Y, Lee SW, Kim DH. Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody. Immune Netw. 2022;22:e4. https:\/\/doi.org\/10.4110\/in.2022.22.e4.","journal-title":"Immune Netw"},{"key":"1803_CR206","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1038\/s41591-025-03898-y","volume":"31","author":"SJ Klempner","year":"2025","unstructured":"Klempner SJ, Sundar R. Evolution of claudin18.2 therapies in gastroesophageal cancers. Nat Med. 2025;31:2861\u20132. https:\/\/doi.org\/10.1038\/s41591-025-03898-y.","journal-title":"Nat Med"},{"key":"1803_CR207","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.Cd-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE. The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development. Cancer Discov. 2024;14:2089\u2013108. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0708.","journal-title":"Cancer Discov"},{"key":"1803_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduction and Targeted Therapy. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"1803_CR209","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361. https:\/\/doi.org\/10.1038\/s41573-023-00709-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1803_CR210","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72:165\u201382. https:\/\/doi.org\/10.3322\/caac.21705.","journal-title":"CA Cancer J Clin"},{"key":"1803_CR211","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/jco.23.00013","volume":"41","author":"A Passaro","year":"2023","unstructured":"Passaro A, J\u00e4nne PA, Peters S. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies. J Clin Oncol. 2023;41:3747\u201361. https:\/\/doi.org\/10.1200\/jco.23.00013.","journal-title":"J Clin Oncol"},{"key":"1803_CR212","doi-asserted-by":"publisher","first-page":"434420","DOI":"10.1200\/JCO.2023.41.36_suppl.434420","volume":"41","author":"R-H Xu","year":"2023","unstructured":"Xu R-H, et al. A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric\/gastroesophageal junction cancer. J Clin Oncol. 2023;41:434420\u2013434420. https:\/\/doi.org\/10.1200\/JCO.2023.41.36_suppl.434420.","journal-title":"J Clin Oncol"},{"key":"1803_CR213","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227\u201338. https:\/\/doi.org\/10.1016\/s1470-2045(24)00636-3.","journal-title":"Lancet Oncol"},{"key":"1803_CR214","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2023.41.16_suppl.3016","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant\/refractory solid tumors. J Clin Oncol. 2023;41:3016\u20133016. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3016.","journal-title":"J Clin Oncol"},{"key":"1803_CR215","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1200\/JCO.2024.42.16_suppl.3028","volume":"42","author":"C Bai","year":"2024","unstructured":"Bai C, et al. A phase 1\/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric\/gastroesophageal junction cancer. J Clin Oncol. 2024;42:3028\u20133028. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3028.","journal-title":"J Clin Oncol"},{"key":"1803_CR216","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/S0959-8049(22)00911-X","volume":"174","author":"W Huang","year":"2022","unstructured":"Huang W, et al. Preclinical activity for TPX-4589 (LM-302), an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumors. Eur J Cancer. 2022;174:S41\u20132. https:\/\/doi.org\/10.1016\/S0959-8049(22)00911-X.","journal-title":"Eur J Cancer"},{"key":"1803_CR217","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2025.43.4_suppl.456","volume":"43","author":"J Ma","year":"2025","unstructured":"Ma J, et al. Safety and preliminary efficacy of ATG-022 in patients with advanced\/metastatic gastric cancer (CLINCH). J Clin Oncol. 2025;43:456\u2013456. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.456.","journal-title":"J Clin Oncol"},{"key":"1803_CR218","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.2024.42.16_suppl.3032","volume":"42","author":"S Bishnoi","year":"2024","unstructured":"Bishnoi S, et al. An open-label, multicenter, phase I study of ATG-022 in patients with advanced\/metastatic solid tumors (CLINCH). J Clin Oncol. 2024;42:3032\u20133032. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3032.","journal-title":"J Clin Oncol"},{"key":"1803_CR219","doi-asserted-by":"publisher","unstructured":"Chen P et al. Abstract 1143: ATG-022, an antibody-drug conjugate targeting Claudin 18.2, demonstrated potent in vivo efficacy in gastric cancer patient-derived xenografts. Cancer Research 82, 1143\u20131143. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-1143 (2022).","DOI":"10.1158\/1538-7445.AM2022-1143"},{"key":"1803_CR220","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","volume":"23","author":"P Flynn","year":"2024","unstructured":"Flynn P, Suryaprakash S, Grossman D, Panier V, Wu J. The antibody-drug conjugate landscape. Nat Rev Drug Discov. 2024;23:577\u20138. https:\/\/doi.org\/10.1038\/d41573-024-00064-w.","journal-title":"Nat Rev Drug Discov"},{"key":"1803_CR221","doi-asserted-by":"publisher","first-page":"2229101","DOI":"10.1080\/19420862.2023.2229101","volume":"15","author":"H Maecker","year":"2023","unstructured":"Maecker H, Jonnalagadda V, Bhakta S, Jammalamadaka V, Junutula JR. Exploration of the antibody-drug conjugate clinical landscape. MAbs. 2023;15:2229101. https:\/\/doi.org\/10.1080\/19420862.2023.2229101.","journal-title":"MAbs"},{"key":"1803_CR222","doi-asserted-by":"publisher","first-page":"114408","DOI":"10.1016\/j.biopha.2023.114408","volume":"161","author":"A Samantasinghar","year":"2023","unstructured":"Samantasinghar A, et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother. 2023;161:114408. https:\/\/doi.org\/10.1016\/j.biopha.2023.114408.","journal-title":"Biomed Pharmacother"},{"key":"1803_CR223","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1200\/JCO.2025.43.16_suppl.4017","volume":"43","author":"X Yu","year":"2025","unstructured":"Yu X, et al. Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343. J Clin Oncol. 2025;43:4017\u20134017. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4017.","journal-title":"J Clin Oncol"},{"key":"1803_CR224","doi-asserted-by":"publisher","unstructured":"Spisek R. 2P SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression. ESMO Open. 2023;8. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101196.","DOI":"10.1016\/j.esmoop.2023.101196"},{"key":"1803_CR225","doi-asserted-by":"publisher","first-page":"CT010","DOI":"10.1158\/1538-7445.AM2025-CT010","volume":"85","author":"R-H Xu","year":"2025","unstructured":"Xu R-H, et al. Abstract CT010: Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors. Cancer Res. 2025;85:CT010\u2013010. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-CT010.","journal-title":"Cancer Res"},{"key":"1803_CR226","doi-asserted-by":"publisher","first-page":"TPS3163","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3163","volume":"42","author":"AG Raufi","year":"2024","unstructured":"Raufi AG, et al. CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors. J Clin Oncol. 2024;42:TPS3163\u20133163. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS3163.","journal-title":"J Clin Oncol"},{"key":"1803_CR227","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1200\/JCO.2025.43.16_suppl.3026","volume":"43","author":"X Cheng","year":"2025","unstructured":"Cheng X, et al. First in human phase I study of TQB2103, a Claudin18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol. 2025;43:3026\u20133026. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3026.","journal-title":"J Clin Oncol"},{"key":"1803_CR228","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1200\/JCO.2024.42.16_suppl.4142","volume":"42","author":"Z Jin","year":"2024","unstructured":"Jin Z, et al. FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): Preliminary results from the phase 1b study. J Clin Oncol. 2024;42:4142\u20134142. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4142.","journal-title":"J Clin Oncol"},{"key":"1803_CR229","doi-asserted-by":"publisher","first-page":"TPS4201","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4201","volume":"43","author":"L Shen","year":"2025","unstructured":"Shen L, et al. A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G\/GEJA): Trial in progress. J Clin Oncol. 2025;43:TPS4201\u20134201. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS4201.","journal-title":"J Clin Oncol"},{"key":"1803_CR230","doi-asserted-by":"publisher","first-page":"TPS507","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS507","volume":"43","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, et al. CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC\/GEJC). J Clin Oncol. 2025;43:TPS507\u2013507. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.TPS507.","journal-title":"J Clin Oncol"},{"key":"1803_CR231","doi-asserted-by":"publisher","first-page":"TPS429","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS429","volume":"42","author":"M Pelster","year":"2024","unstructured":"Pelster M, et al. A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2. J Clin Oncol. 2024;42:TPS429\u2013429. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.TPS429.","journal-title":"J Clin Oncol"},{"key":"1803_CR232","doi-asserted-by":"publisher","first-page":"S1203","DOI":"10.1016\/j.annonc.2025.08.2758","volume":"36","author":"T Deng","year":"2025","unstructured":"Deng T, et al. 2139P SKB315, a novel claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors including gastric\/ gastroesophageal junction cancer (GC\/GEJC): A phase I study. Ann Oncol. 2025;36:S1203\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2758.","journal-title":"Ann Oncol"},{"key":"1803_CR233","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12943-025-02476-7","volume":"24","author":"D Shang","year":"2025","unstructured":"Shang D, et al. Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives. Mol Cancer. 2025;24:281. https:\/\/doi.org\/10.1186\/s12943-025-02476-7.","journal-title":"Mol Cancer"},{"key":"1803_CR234","doi-asserted-by":"publisher","first-page":"152430","DOI":"10.1016\/j.seminoncol.2025.152430","volume":"52","author":"S Sharif","year":"2025","unstructured":"Sharif S, Sharma U, Yadav AK. CAR-T cell therapy: A therapeutic strategy for cancer treatment. Semin Oncol. 2025;52:152430. https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152430.","journal-title":"Semin Oncol"},{"key":"1803_CR235","doi-asserted-by":"publisher","first-page":"835762","DOI":"10.3389\/fimmu.2022.835762","volume":"13","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol. 2022;13:835762. https:\/\/doi.org\/10.3389\/fimmu.2022.835762.","journal-title":"Front Immunol"},{"key":"1803_CR236","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaneurol.2024.3818","volume":"82","author":"FS Ismail","year":"2025","unstructured":"Ismail FS, et al. Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review. JAMA Neurol. 2025;82:93\u2013103. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3818.","journal-title":"JAMA Neurol"},{"key":"1803_CR237","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: The evolution of CAR-T cell therapy. Mol Ther. 2025;33:2123\u201340. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.005.","journal-title":"Mol Ther"},{"key":"1803_CR238","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD, Improving. CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103941.","journal-title":"EBioMedicine"},{"key":"1803_CR239","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-023-01491-9","volume":"16","author":"C Qi","year":"2023","unstructured":"Qi C, et al. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. J Hematol Oncol. 2023;16:102. https:\/\/doi.org\/10.1186\/s13045-023-01491-9.","journal-title":"J Hematol Oncol"},{"key":"1803_CR240","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/s0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405:2049\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(25)00860-8.","journal-title":"Lancet"},{"key":"1803_CR241","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30:2224\u201334. https:\/\/doi.org\/10.1038\/s41591-024-03037-z.","journal-title":"Nat Med"},{"key":"1803_CR242","doi-asserted-by":"publisher","unstructured":"Zhao X, et al. 1458 Efficacy and immunomodulatory of Claudin18.2-specific IL-7\/XCL1 armored CAR-T cells in digestive tract cancers. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1458.","DOI":"10.1136\/jitc-2024-SITC2024.1458"},{"key":"1803_CR243","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1200\/JCO.2025.43.16_suppl.4022","volume":"43","author":"DB Zhen","year":"2025","unstructured":"Zhen DB, et al. Preliminary results of a phase 1 study of LB1908, an autologous Claudin 18.2\u2013targeted chimeric antigen receptor T-cell product, in patients with advanced gastroesophageal adenocarcinoma. J Clin Oncol. 2025;43:4022\u20134022. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4022.","journal-title":"J Clin Oncol"},{"key":"1803_CR244","doi-asserted-by":"publisher","first-page":"263","DOI":"10.21147\/j.issn.1000-9604.2020.02.13","volume":"32","author":"J Zhang","year":"2020","unstructured":"Zhang J, Dong R, Shen L. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. Chin J Cancer Res. 2020;32:263\u201370. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2020.02.13.","journal-title":"Chin J Cancer Res"},{"key":"1803_CR245","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer. J Transl Med. 2023;21:255. https:\/\/doi.org\/10.1186\/s12967-023-04080-z.","journal-title":"J Transl Med"},{"key":"1803_CR246","doi-asserted-by":"publisher","first-page":"100916","DOI":"10.1016\/j.xgen.2025.100916","volume":"5","author":"L Liu","year":"2025","unstructured":"Liu L, et al. CXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST. Cell Genom. 2025;5:100916. https:\/\/doi.org\/10.1016\/j.xgen.2025.100916.","journal-title":"Cell Genom"},{"key":"1803_CR247","doi-asserted-by":"publisher","first-page":"122871","DOI":"10.1016\/j.biomaterials.2024.122871","volume":"314","author":"H Li","year":"2025","unstructured":"Li H, et al. Enhancing CAR-T cell therapy against solid tumor by drug-free triboelectric immunotherapy. Biomaterials. 2025;314:122871. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122871.","journal-title":"Biomaterials"},{"key":"1803_CR248","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma L, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365:162\u20138. https:\/\/doi.org\/10.1126\/science.aav8692.","journal-title":"Science"},{"key":"1803_CR249","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, et al. CAR-T therapy in solid tumors. Cancer Cell. 2025;43:665\u201379. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.019.","journal-title":"Cancer Cell"},{"key":"1803_CR250","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10:210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Signal Transduct Target Ther"},{"key":"1803_CR251","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41416-025-03100-7","volume":"133","author":"J Zhou","year":"2025","unstructured":"Zhou J. Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer. Br J Cancer. 2025;133:919\u201336. https:\/\/doi.org\/10.1038\/s41416-025-03100-7.","journal-title":"Br J Cancer"},{"key":"1803_CR252","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41573-025-01237-x","volume":"24","author":"S Wang","year":"2025","unstructured":"Wang S, Weissman D, Dong Y. RNA chemistry and therapeutics. Nat Rev Drug Discovery. 2025;24:828\u201351. https:\/\/doi.org\/10.1038\/s41573-025-01237-x.","journal-title":"Nat Rev Drug Discovery"},{"key":"1803_CR253","doi-asserted-by":"publisher","DOI":"10.1039\/D5PM00159E","author":"SK Niazi","year":"2026","unstructured":"Niazi SK. mRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework. RSC Pharm. 2026. https:\/\/doi.org\/10.1039\/D5PM00159E.","journal-title":"RSC Pharm"},{"key":"1803_CR254","doi-asserted-by":"publisher","first-page":"20891","DOI":"10.1038\/s41598-025-05105-x","volume":"15","author":"Y An","year":"2025","unstructured":"An Y, et al. Identification of a LncRNA based CeRNA network signature to establish a prognostic model and explore potential therapeutic targets in gastric cancer. Sci Rep. 2025;15:20891. https:\/\/doi.org\/10.1038\/s41598-025-05105-x.","journal-title":"Sci Rep"},{"key":"1803_CR255","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.omtm.2025.101463","volume":"33","author":"S Xu","year":"2025","unstructured":"Xu S, Hu Z, Song F, Xu Y, Han X. Lipid nanoparticles: Composition, formulation, and application. Mol Ther Methods Clin Dev. 2025;33:101463. https:\/\/doi.org\/10.1016\/j.omtm.2025.101463.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1803_CR256","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1021\/acsabm.5c00076","volume":"8","author":"H Zhang","year":"2025","unstructured":"Zhang H, et al. Cyclic Acetal-Based Lipid Nanoparticles Deliver mRNA In Vivo for Tumor Immunotherapy. ACS Appl Bio Mater. 2025;8:3888\u201398. https:\/\/doi.org\/10.1021\/acsabm.5c00076.","journal-title":"ACS Appl Bio Mater"},{"key":"1803_CR257","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.7150\/thno.82228","volume":"13","author":"Y Granot-Matok","year":"2023","unstructured":"Granot-Matok Y, et al. Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors. Theranostics. 2023;13:3497\u2013508. https:\/\/doi.org\/10.7150\/thno.82228.","journal-title":"Theranostics"},{"key":"1803_CR258","doi-asserted-by":"publisher","first-page":"2255041","DOI":"10.1080\/2162402x.2023.2255041","volume":"12","author":"H B\u00e4hr-Mahmud","year":"2023","unstructured":"B\u00e4hr-Mahmud H, et al. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody. Oncoimmunology. 2023;12:2255041. https:\/\/doi.org\/10.1080\/2162402x.2023.2255041.","journal-title":"Oncoimmunology"},{"key":"1803_CR259","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022;40:840\u201354. https:\/\/doi.org\/10.1038\/s41587-022-01294-2.","journal-title":"Nat Biotechnol"},{"key":"1803_CR260","doi-asserted-by":"publisher","first-page":"107534","DOI":"10.1016\/j.biotechadv.2020.107534","volume":"40","author":"Y Weng","year":"2020","unstructured":"Weng Y, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534. https:\/\/doi.org\/10.1016\/j.biotechadv.2020.107534.","journal-title":"Biotechnol Adv"},{"key":"1803_CR261","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41551-023-01131-0","volume":"8","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, et al. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity. Nat Biomed Eng. 2024;8:544\u201360. https:\/\/doi.org\/10.1038\/s41551-023-01131-0.","journal-title":"Nat Biomed Eng"},{"key":"1803_CR262","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/JCO.2024.42.3_suppl.370","volume":"42","author":"DSG Celso","year":"2024","unstructured":"Celso DSG, et al. Safety and efficacy of zolbetuximab for CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials. J Clin Oncol. 2024;42:370\u2013370. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.370.","journal-title":"J Clin Oncol"},{"key":"1803_CR263","doi-asserted-by":"publisher","first-page":"108763","DOI":"10.1016\/j.pharmthera.2024.108763","volume":"266","author":"K Misawa","year":"2025","unstructured":"Misawa K, Bhat H, Adusumilli PS, Hou Z. Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials. Pharmacol Ther. 2025;266:108763. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108763.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1803_CR264","doi-asserted-by":"publisher","first-page":"August30","DOI":"10.21037\/jgo-2025-564","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, et al. Local radiotherapy polarized tumor-associated macrophages enhance the efficacy of Claudin18.2-targeted CAR-T therapy in pancreatic cancer. J Gastrointest Oncol. 2025;16(4):August30. Journal of Gastrointestinal Oncology (2025).","journal-title":"J Gastrointest Oncol"},{"key":"1803_CR265","doi-asserted-by":"publisher","unstructured":"Ma X, et al. Systemic tumor regression with synergy therapy: radiotherapy and CAR-T. Cell Death Discov. 2024;10. https:\/\/doi.org\/10.1038\/s41420-024-02245-3.","DOI":"10.1038\/s41420-024-02245-3"},{"key":"1803_CR266","doi-asserted-by":"publisher","unstructured":"Liu X, et al. 792 Givastomig, a novel Claudin18.2\/4-1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L\/2L treatment for gastric cancer. J Immunother Cancer. 2023;11. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0792.","DOI":"10.1136\/jitc-2023-SITC2023.0792"},{"key":"1803_CR267","doi-asserted-by":"publisher","unstructured":"Shi M, Yuan H, Yuan F, Zhu Z. 478eTiP IBI343 combined with Sintilimab and SOX as first-Line therapy for CLDN18.2-positive locally advanced unresectable or metastatic HER2-negative gastric\/gastroesophageal junction adenocarcinoma (G\/GEJ AC). Annals of Oncology 36, S1936, https:\/\/doi.org\/10.1016\/j.annonc.2025.10.304 (2025).","DOI":"10.1016\/j.annonc.2025.10.304"},{"key":"1803_CR268","doi-asserted-by":"publisher","first-page":"101710","DOI":"10.1016\/j.xcrm.2024.101710","volume":"5","author":"G Xu","year":"2024","unstructured":"Xu G, et al. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep Med. 2024;5:101710. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101710.","journal-title":"Cell Rep Med"},{"key":"1803_CR269","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41420-024-02167-0","volume":"10","author":"W Xue","year":"2024","unstructured":"Xue W, et al. Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer. Cell Death Discov. 2024;10:393. https:\/\/doi.org\/10.1038\/s41420-024-02167-0.","journal-title":"Cell Death Discov"},{"key":"1803_CR270","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336277","author":"J Liu","year":"2026","unstructured":"Liu J, et al. KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Gut. 2026. https:\/\/doi.org\/10.1136\/gutjnl-2025-336277.","journal-title":"Gut"},{"key":"1803_CR271","doi-asserted-by":"publisher","first-page":"S580","DOI":"10.1016\/j.annonc.2025.08.1515","volume":"36","author":"L Shen","year":"2025","unstructured":"Shen L, et al. 946P Updated efficacy of ASKB589 plus CAPOX\/PD-1 inhibitor in first - line metastatic G\/GEJ adenocarcinoma: Phase Ib\/II study. Ann Oncol. 2025;36:S580\u20131. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1515.","journal-title":"Ann Oncol"},{"key":"1803_CR272","doi-asserted-by":"publisher","unstructured":"Wang Y, et al. 544 A phase I\/II clinical trial of anti-CLDN18.2\/PD-L1 recombinant humanized bispecific antibody Q-1802 combined with XELOX chemotherapy in untreated advanced GC\/GEJ patients. J Immunother Cancer. 2025;13. https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0544.","DOI":"10.1136\/jitc-2025-SITC2025.0544"},{"key":"1803_CR273","doi-asserted-by":"publisher","first-page":"e2510017","DOI":"10.71150\/jm.2510017","volume":"64","author":"HJ Lee","year":"2026","unstructured":"Lee HJ, et al. Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1\/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy. J Microbiol. 2026;64:e2510017. https:\/\/doi.org\/10.71150\/jm.2510017.","journal-title":"J Microbiol"},{"key":"1803_CR274","doi-asserted-by":"publisher","unstructured":"Zhao X, et al. Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7\/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysis. Signal Transduct Target Ther. 2026;11. https:\/\/doi.org\/10.1038\/s41392-026-02621-8.","DOI":"10.1038\/s41392-026-02621-8"},{"key":"1803_CR275","doi-asserted-by":"publisher","first-page":"1638585","DOI":"10.3389\/fimmu.2025.1638585","volume":"16","author":"Y Xing","year":"2025","unstructured":"Xing Y, et al. VHH-based CAR-T cells targeting Claudin 18.2 show high efficacy in pancreatic cancer models. Front Immunol. 2025;16:1638585. https:\/\/doi.org\/10.3389\/fimmu.2025.1638585.","journal-title":"Front Immunol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01803-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01803-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01803-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T22:01:48Z","timestamp":1780869708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01803-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":275,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1803"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01803-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}